Hanjoon Alex  Kim net worth and biography

Hanjoon Kim Biography and Net Worth

Alex Kim is Chief Financial Officer of Standard BioTools and has responsibility for Finance, Accounting, IT, and our Legal and Compliance functions. Alex has a passion for improving healthcare and in building businesses by bringing together teams and capabilities to accelerate the pace of innovative breakthroughs. Previously, Alex was Chief Operating Officer.

Prior to joining Standard BioTools, Alex was President of Milliken’s Healthcare Division, a leading provider of advanced wound care products for human health, animal health, and sports medicine. He joined Milliken in 2015 initially as Executive Vice President of Corporate Strategy and Corporate Development. From 2012 to 2015, he was Senior Vice President of Strategy and Business Development at Pall Corporation.  And from 2002 to 2012, he worked at Danaher Corporation (NYSE:DHR) in a variety of roles in general management, M&A, and business development. Over his career, Alex has completed over 40 transactions, largely focused on healthcare, medical technology, and life sciences. He also brings strong operational execution experience, having been intimately involved in integrations and most recently with full operational leadership of a business. In his early career, Alex worked in a variety of engineering design, product development, and marketing/sales support roles. Alex has a BS in Mechanical Engineering from Carnegie Mellon University, an MS In Mechanical Engineering from University of Pittsburgh, and an MBA from Stanford University.

What is Hanjoon Alex Kim's net worth?

The estimated net worth of Hanjoon Alex Kim is at least $1.34 million as of May 23rd, 2025. Mr. Kim owns 930,286 shares of Standard BioTools stock worth more than $1,339,612 as of December 4th. This net worth evaluation does not reflect any other investments that Mr. Kim may own. Additionally, Mr. Kim receives an annual salary of $468,050.00 as CFO at Standard BioTools. Learn More about Hanjoon Alex Kim's net worth.

How old is Hanjoon Alex Kim?

Mr. Kim is currently 53 years old. There are 3 older executives and no younger executives at Standard BioTools. The oldest executive at Standard BioTools is Dr. Michael Egholm Ph.D., President, CEO & Director, who is 61 years old. Learn More on Hanjoon Alex Kim's age.

What is Hanjoon Alex Kim's salary?

As the CFO of Standard BioTools Inc., Mr. Kim earns $468,050.00 per year. The highest earning executive at Standard BioTools is Dr. Michael Egholm Ph.D., President, CEO & Director, who commands a salary of $640,340.00 per year. Learn More on Hanjoon Alex Kim's salary.

How do I contact Hanjoon Alex Kim?

The corporate mailing address for Mr. Kim and other Standard BioTools executives is 2 Tower Place Ste 2000, South San Francisco CA, 94080. Standard BioTools can also be reached via phone at (650) 266-6000 and via email at [email protected]. Learn More on Hanjoon Alex Kim's contact information.

Has Hanjoon Alex Kim been buying or selling shares of Standard BioTools?

Hanjoon Alex Kim has not been actively trading shares of Standard BioTools over the course of the past ninety days. Most recently, Hanjoon Alex Kim sold 1,428 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $0.94, for a transaction totalling $1,342.32. Following the completion of the sale, the chief financial officer now directly owns 930,286 shares of the company's stock, valued at $874,468.84. Learn More on Hanjoon Alex Kim's trading history.

Who are Standard BioTools' active insiders?

Standard BioTools' insider roster includes Michael Egholm (President & CEO), Hanjoon Kim (CFO), and Sean Mackay (SVP). Learn More on Standard BioTools' active insiders.

Are insiders buying or selling shares of Standard BioTools?

In the last twelve months, Standard BioTools insiders bought shares 24 times. They purchased a total of 17,279,179 shares worth more than $21,064,912.74. In the last twelve months, insiders at the sold shares 9 times. They sold a total of 58,089 shares worth more than $57,450.84. The most recent insider tranaction occured on December, 4th when Director Casdin Partners Master Fund, L bought 150,000 shares worth more than $217,500.00. Insiders at Standard BioTools own 23.2% of the company. Learn More about insider trades at Standard BioTools.

Information on this page was last updated on 12/4/2025.

Hanjoon Alex Kim Insider Trading History at Standard BioTools

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/23/2025Sell1,428$0.94$1,342.32930,286View SEC Filing Icon  
5/22/2025Sell1,355$1.00$1,355.00931,714View SEC Filing Icon  
5/21/2025Sell1,407$1.03$1,449.21933,069View SEC Filing Icon  
See Full Table

Hanjoon Alex Kim Buying and Selling Activity at Standard BioTools

This chart shows Hanjoon Alex Kim's buying and selling at Standard BioTools by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Standard BioTools Company Overview

Standard BioTools logo
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $1.44
Low: $1.39
High: $1.47

50 Day Range

MA: $1.30
Low: $1.12
High: $1.51

2 Week Range

Now: $1.44
Low: $0.92
High: $2.25

Volume

1,185,059 shs

Average Volume

2,075,536 shs

Market Capitalization

$553.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24